Healthcare
Riverside adds to Australia workplace wellbeing rollup play
The Riverside Group has bought Australian injury management and occupational rehabilitation services provider Nabenet as part of a workplace wellbeing rollup strategy.
Alibaba leads Series D for China cancer test kit business
Guangzhou-based Creative Biosciences, which manufacturers kits that test for colon cancer, has raised a RMB560 million ($88 million) Series D led by Alibaba Group.
Korea GPs invest $40m in Singapore biotech player
A group of Korean private equity investors has committed $40 million in funding to Ceracin, a Singapore-based biotech developer focused on neurotherapeutics.
Japan digitization: Easy targets, hard to hit
Japan’s massive mid-sized business sector is still trading in its fax machines for the cloud, sometimes willingly, sometimes begrudgingly. PE’s help is most needed in terms of mindset
China's Vitalbridge closes Fund II at $275m
Vitalbridge Capital, a China-based venture capital firm that spun out from Trustbridge Partners, has raised $275 million for its second US dollar-denominated fund.
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
PE-backed MicroTech Medical targets $254m Hong Kong IPO
MicroTech Medical, a China-based manufacturer of insulin pumps for diabetes sufferers that counts Lilly Asia Ventures (LAV) and Qiming Venture Partners among its investors, is looking to raise up to HK$1.98 billion ($254 million) in a Hong Kong IPO.
China biotech start-up LianBio files for US IPO
LianBio, a two-year-old Chinese biotech start-up incubated by life sciences investor Perceptive Advisors, has filed for a US IPO.
China biotech: Going global
A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
Deal focus: COVID-19 grows India’s Medikabazaar
Pandemic-driven demand for masks, ventilators, and the like has propelled Indian medical equipment operator Medikabazaar to its next stage of development with a global mix of investors
GP profile: Advent Partners
Having spent the first half of the last decade undergoing a renewal in terms of leadership and strategy, Australia’s Advent Partners believes it has emerged stronger, smarter, and more focused on the future
CDC joins $75m round for India medical B2B marketplace
CDC Group has contributed $27.5 million to a $75 million Series C round for Medikabazaar, an Indian medical B2B marketplace and COVID-19 supply chain operator.
China's Broncus raises $215m in IPO, struggles on HK debut
Broncus Holding Corporation, a China-based manufacturer of medical devices used to treat lung diseases, plunged 12.8% on its Hong Kong trading debut following a HK$1.67 billion ($215 million) IPO.
Eight Roads' China hospital wins backing from Swire
DeltaHealth, a China-based cardiovascular care chain established by Eight Roads, has raised $100 million in funding led by Hong Kong-listed conglomerate Swire Pacific.
IFC plans re-up for A91's second India fund
The International Finance Corporation (IFC) has proposed a commitment of up to $25 million in the sophomore fund of India’s A91 Partners, which has a target of $500-550 million.
Hong Kong's Prenetics agrees $1.25b SPAC merger
Hong Kong-based genetic testing business Prenetics has agreed to merge with a special purpose acquisition company (SPAC) sponsored by Adrian Cheng, scion of local property developer New World Development and managing partner of C Ventures, at an enterprise...
Apax-owned Healthium Medtech files for India IPO
Apax Partners-owned Helthium Medtech, an India-based medical devices manufacturer formerly known as Sutures India, has filed for a domestic IPO.
CVC buys into Chinese pharmacy chain
CVC Capital Partners has made an investment of undisclosed size in Xi’an Yikang Pharmacy, China’s eighth-largest pharmacy chain.
AGIC raises $1.2b for second Europe-Asia fund
AGIC Capital, a private equity firm that focuses on cross-border investments along the China-Europe axis, has closed its second fund with $1.2 billion in commitments.
Hong Kong’s OrbusNeich raises $200m
Hong Kong-based medical devices maker OrbusNeich Medical Group has raised about $200 million across two rounds featuring Shenzhen Capital Group and its Red Earth Healthcare Investment Fund.
Deal focus: Singapore's Doctor Anywhere raises $65m Series C
Doctor Anywhere’s omnichannel approach to digitizing Southeast Asian healthcare is luring investors with eyes on the pandemic’s most logical trend. Preserving a first-mover advantage is the challenge
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.
China cancer treatment specialist Ionova raises $100m
Tsing Song Capital, a Chinese healthcare-focused private equity firm, has led a $100 million round for Ionova Life Science, a local biotech player specializing in cancer treatments.
